How Is Tardive Dyskinesia from Reglan Diagnosed in Texas?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational and Legal Accountability

If you or a loved one has developed unusual, involuntary movements after taking Reglan, you may be facing tardive dyskinesia. This condition can be subtle at first, but early recognition is critical. The medical community's evolving understanding of drug-induced movement disorders has sharpened diagnostic tools, yet many patients remain unaware of the signs. This page explains how tardive dyskinesia from Reglan is diagnosed and what steps you can take to stay informed.

Reglan and Tardive Dyskinesia: The Medical Evidence

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux disease (GERD) and diabetic gastroparesis. The FDA-approved labeling explicitly states that Reglan tablets are indicated for treatment of GERD for 4 to 12 weeks and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that Reglan has not been shown to be safe and effective for GERD beyond 12 weeks and is not recommended for pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The FDA boxed warning for Reglan states that metoclopramide can cause TD, and the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further notes that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the labeling advises avoiding total treatment duration longer than 12 weeks, and if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism of Action and Risk Factors for Tardive Dyskinesia

The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine D2 receptor antagonist in the central nervous system. Chronic blockade of these receptors in the basal ganglia is thought to lead to upregulation and supersensitivity of dopamine receptors, which can manifest as the involuntary movements characteristic of TD. The FDA warnings and precautions section notes that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is a critical clinical consideration, as it may allow TD to progress unrecognized while the patient continues taking the drug. For patients in Texas who have developed TD after using Reglan, the statute of limitations is a key legal consideration. Texas law generally imposes a two-year statute of limitations for personal injury claims, including those related to prescription drug injuries. The clock typically starts running from the date the injury was discovered or reasonably should have been discovered. Given that TD can develop insidiously and may be masked by continued metoclopramide use, the discovery date may be delayed until a physician diagnoses the condition or the patient becomes aware of the abnormal movements. The FDA labeling emphasizes that TD can be potentially irreversible and disfiguring, and that immediate discontinuation of Reglan is required if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This underscores the importance of early recognition and prompt cessation of the drug to minimize harm.

Settlement Considerations and Legal Context in Texas

Settlement-related considerations for affected patients include the adequacy of warnings provided by the manufacturer. The FDA boxed warning clearly states the risk of TD and the need for short-term use, but patients may have been prescribed Reglan for extended periods without appropriate monitoring or warning. The labeling also advises avoiding concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was not informed of these risks or was prescribed Reglan beyond the recommended duration, this could form the basis of a claim. The timeline between exposure and documented harm is critical: TD may not appear until months or years after starting Reglan, and the cumulative dosage is a known risk factor. Patients who used Reglan for longer than 12 weeks, especially those with diabetic gastroparesis, are at higher risk. In summary, Reglan carries a clear FDA boxed warning about TD risk, with specific guidance on treatment duration and monitoring. Patients in Texas who developed TD after using Reglan should be aware of the two-year statute of limitations from the date of discovery. The mechanistic link between metoclopramide and TD is well-established, and the adequacy of warnings provided to patients is a central issue in potential settlements. Early diagnosis and discontinuation of Reglan are essential to prevent progression of TD, which may be irreversible.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Texas?

Texas law generally imposes a two-year statute of limitations for personal injury claims, including those related to prescription drug injuries. The clock typically starts running from the date the injury was discovered or reasonably should have been discovered. Given that tardive dyskinesia can develop insidiously and may be masked by continued metoclopramide use, the discovery date may be delayed until a physician diagnoses the condition or the patient becomes aware of the abnormal movements.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) acts as a dopamine D2 receptor antagonist in the central nervous system. Chronic blockade of these receptors in the basal ganglia is thought to lead to upregulation and supersensitivity of dopamine receptors, which can manifest as the involuntary movements characteristic of tardive dyskinesia. The FDA warns that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the FDA warnings about Reglan and tardive dyskinesia?

The FDA boxed warning for Reglan states that metoclopramide can cause tardive dyskinesia, and the risk increases with duration of treatment and total cumulative dosage. The warning notes that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Reglan

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.